Vitamin D and cardiovascular disease: Is the evidence solid?

European Heart Journal

Volumn 34, Issue 48, 2013, Pages 3691-3698

  Al Mheid, Ibhar ^a   Patel, Riyaz S ^b   Tangpricha, Vin ^a,c   Quyyumi, Arshed A ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Vascular risk factors; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; PLACEBO; VITAMIN D; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; DIABETES MELLITUS; DIETARY INTAKE; DOSE RESPONSE; ENDOTHELIUM CELL; GLYCEMIC CONTROL; HEART MUSCLE CELL; HUMAN; HYDROXYLATION; HYPERTENSION; NONHUMAN; PATHOGENESIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULITIS; VITAMIN D DEFICIENCY;

CARDIOVASCULAR DISEASE; VASCULAR RISK FACTORS; VITAMIN D;

ADAPTIVE IMMUNITY; ANIMALS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; ENDOTHELIAL CELLS; HUMANS; MYOCYTES, CARDIAC; RATS; RECEPTORS, CALCITRIOL; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84884161864     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht166     Document Type: Review

References (121)

1. McDonnell DP, Mangelsdorf DJ, Pike JW, Haussler MR, O'Malley BW. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science 1987;235:1214-1217.
2. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, Murad MH, Kovacs CS. The nonskeletal effects of vitamin D: An endocrine society scientific statement. Endocr Rev 2012;33:456-492.
3. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev 1992;13:719-764.
4. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999;20:321-344.
5. Zhao G, Simpson RU. Membrane localization, caveolin-3 association and rapid actions of vitamin D receptor in cardiac myocytes. Steroids 2010;75:555-559.
6. Farach-Carson MC, Ridall AL. Dual 1,25-dihydroxyvitamin D3 signal response pathways in osteoblasts: Cross-Talk between genomic and membrane-initiated pathways. Am J Kidney Dis 1998;31:729-742.
7. Giovannucci E. The epidemiology of vitaminDand cancer incidence and mortality: A review (United States). Cancer Causes Control 2005;16:83-95.
8. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997;30:150-156.
9. Cucu F, Schioiu-Costache L, Damsa T, Steinbach M. Effects of a multifactorial prevention trial of coronary heart disease on the seasonal variation of the incidence of major cardiovascular events. Rom J Int Med 1992;30:175-185.
10. Intersalt: An International Study of electrolyte excretion and blood pressure. Results for 24 h urinary sodiumand potassium excretion. Intersalt cooperative research group. BMJ 1988;297:319-328.
11. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
12. Wang J, Luben R, Khaw KT, Bingham S,Wareham NJ, Forouhi NG. Dietary energy density predicts the risk of incident type 2 diabetes: The European Prospective Investigation of Cancer (epic)-norfolk Study. Diabetes Care 2008;31:2120-2125.
13. Melamed ML, Michos ED, PostW, Astor B. 25-hydroxyvitaminDlevels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629-1637.
14. Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 2011;124:1838-1847.
15. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 2002;13:621-629.
16. O'Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU. 1,25-dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997;272:H1751-H1758.
17. Simpson RU. Selective knockout of the vitamin D receptor in the heart results in cardiac hypertrophy: Is the heart a drugable target for vitaminDreceptor agonists? Circulation 2011;124:1808-1810.
18. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-Angiotensin systems. Am J Physiol 2005;288:E125-E132.
19. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996;97:1577-1588.
20. Weishaar RE, Kim SN, Saunders DE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990;258:E134-E142.
21. Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 2008;51:559-564.
22. Bodyak N, Ayus JC, Achinger S, ShivalingappaV, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM. Activated vitaminDattenuates left ventricular abnormalities induced by dietary sodium in DAHL salt-sensitive animals. Proc Natl Acad Sci USA 2007;104:16810-16815.
23. Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E. Identification and regulation of 1,25- dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989; 83:1903-1915.
24. Raymond MA, Desormeaux A, Labelle A, Soulez M, Soulez G, Langelier Y, Pshezhetsky AV, Hebert MJ. Endothelial stress induces the release of vitamin D-binding protein, a novel growth factor. Biochem Biophys Res Commun 2005; 338:1374-1382.
25. Martinesi M, Bruni S, Stio M, Treves C. 1,25-dihydroxyvitamin D3 inhibits tumor necrosis factor-Alpha-induced adhesion molecule expression in endothelial cells. Cell Biol Int 2006;30:365-375.
26. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, Rashid G. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008;294:F1059-F1064.
27. Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008;295:H289-H296.
28. Li YC, Kong J,Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-Angiotensin system. J Clin Invest 2002; 110:229-238.
29. Motiwala SR,Wang TJ. VitaminDand cardiovascular risk. Curr Hypertens Rep 2012; 14:209-218.
30. Kempker JA, Tangpricha V, Ziegler TR, Martin GS. Vitamin D in sepsis: From basic science to clinical impact. Crit Care 2012;16:316.
31. Judd SE, Nanes MS, Ziegler TR,WilsonPW, TangprichaV. Optimal vitaminDstatus attenuates the age-Associated increase in systolic blood pressure in white Americans: Results from the third national health and nutrition examination survey. Am J Clin Nutr 2008;87:136-141.
32. Pilz S, Tomaschitz A, Ritz E, Pieber TR. VitaminDstatus and arterial hypertension: A systematic review. Nature Rev 2009;6:621-630.
33. Vaidya A, Williams JS. The relationship between vitamin D and the renin-Angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism 2012;61:450-458.
34. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 1986;105:649-654.
35. Vaidya A, Forman JP, Hopkins PN, Seely EW, Williams JS. 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst 2011;12:311-319.
36. Burgess ED, Hawkins RG, Watanabe M. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens 1990;3:903-905.
37. Vaidya A, Sun B, LarsonC, Forman JP, Williams JS. Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: An interventional study. J Clin Endocrinol Metab 2012;97: 2456-2465.
38. Morganti A, Ambrosi B, Sala C, Cianci L, Bochicchio D, Turolo L, Zanchetti A. Effects of angiotensin ii blockade on the responses of the pituitary-Adrenal axis to corticotropin-releasing factor in humans. J Cardiovasc Pharmacol 1987; 10(Suppl. 7):S167-S169.
39. Quyyumi AA, Patel RS. Endothelial dysfunction and hypertension: Cause or effect? Hypertension 2010;55:1092-1094.
40. Patel RS, Al Mheid I, Morris AA, Ahmed Y, Kavtaradze N, Ali S, Dabhadkar K, Brigham K, Hooper WC, Alexander RW, Jones DP, Quyyumi AA. Oxidative stress is associated with impaired arterial elasticity. Atherosclerosis2011;218:90-95.
41. Pirro M, Manfredelli MR, Helou RS, Scarponi AM, Schillaci G, Bagaglia F, Melis F, Mannarino E. Association of parathyroid hormone and 25-OH-vitamin D levels with arterial stiffness in postmenopausal women with vitamin D insufficiency. J Atheroscler Thromb 2012.
42. Lee JI, Oh SJ, Ha WC, Kwon HS, Sohn TS, Son HS, Cha BY. Serum 25-hydroxyvitamin D concentration and arterial stiffness among type 2 diabetes. Diabetes Res Clin Pract 2012;95:42-47.
43. Reynolds JA, Haque S, Berry JL, Pemberton P, Teh LS, Ho P, Gorodkin R, Bruce IN. 25-hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2012;51: 544-551.
44. Zagura M, Serg M, Kampus P, Zilmer M, Eha J, Unt E, Lieberg J, Cockcroft JR, Kals J. Aortic stiffness and vitamin D are independent markers of aortic calcification in patients with peripheral arterial disease and in healthy subjects. Eur J Vasc Endovasc Surg 2011;42:689-695.
45. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F. Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitaminDdeficiency. J AmSoc Nephrol 2007;18:613-620.
46. Rezai MR, Wallace AM, Sattar N, Finn JD, Wu FC, Cruickshank JK. Ethnic differences in aortic pulse wave velocity occur in the descending aorta and may be related to vitamin D. Hypertension 2011;58:247-253.
47. Giallauria F, Milaneschi Y, Tanaka T, Maggio M, Canepa M, Elango P, Vigorito C, Lakatta EG, Ferrucci L, Strait J. Arterial stiffness and vitamin Dlevels: The Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2012.
48. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, Toprak A, Yazici D, Sancak S, Deyneli O, Akalin S. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 2009;94: 4023-4030.
49. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008;25:320-325.
50. Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, Li K, Bassali R, Guo DH, Thomas J, Pierce GL, White J, Holick MF, Zhu H. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab 2010;95:4584-4591.
51. Gepner AD, Ramamurthy R, Krueger DC, Korcarz CE, Binkley N, Stein JH. A prospective randomized controlled trial of the effects of vitaminDsupplementation on cardiovascular disease risk. PLoS ONE 2012;7:e36617.
52. Martins D,Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, MehrotraR, Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitaminDin the United States: Datafrom the third national health and nutrition examination survey. Arch Intern Med 2007;167:1159-1165.
53. Hypponen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008;57:298-305.
54. Hintzpeter B, Mensink GB, ThierfelderW, Muller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr 2008;62: 1079-1089.
55. Pasco JA, Henry MJ, Nicholson GC, Brennan SL, Kotowicz MA. Behavioural and physical characteristics associated with vitamin D status in women. Bone 2009; 44:1085-1091.
56. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: The medical research council Ely prospective study 1990-2000. Diabetes 2008;57: 2619-2625.
57. Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young middle-eastern population. Eur J Endocrinol 2009;160:965-971.
58. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008;52:828-832.
59. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49:1063-1069.
60. Ketteler M, Martin KJ,Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the impact SHPT study. Nephrol Dial Transplant 2012;27: 3270-3278.
61. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008;73:1355-1363.
62. Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 1995;49:640-646.
63. Pfeifer M, Begerow B, MinneHW, Nachtigall D, Hansen C. Effects of a short-Term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001;86:1633-1637.
64. Witham MD, Nadir MA, Struthers AD. Effect of vitaminDon blood pressure: A systematic review and meta-Analysis. J Hypertens 2009;27:1948-1954.
65. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010;152:307-314.
66. WuSH, Ho SC, Zhong L. Effects of vitamin Dsupplementation on blood pressure. South Med J 2010;103:729-737.
67. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A, Erwin PJ, Hensrud DD, Murad MH, Montori VM. Vitamin D and cardiovascular outcomes: A systematic review and meta-Analysis. J Clin Endocrinol Metab 2011;96:1931-1942.
68. Weber KT, Rosenberg EW, Sayre RM. Suberythemal ultraviolet exposure and reduction in blood pressure. Am J Med 2004;117:281-282.
69. Krause R, Buhring M, HopfenmullerW, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet 1998;352:709-710.
70. Forssander CA. Pre-erythema blood pressure changes following ultraviolet irradiation. Can Med Assoc J 1956;74:730-733.
71. Ergenekon E, Gucuyener K, Dursun H, Erbas D, Ozturk G, Koc E, Atalay Y. Nitric oxide production in newborns under phototherapy. Nitric Oxide 2002;6:69-72.
72. Buyukafsar K, Levent A, Un I, Ark M, Arikan O, Ozveren E. Mediation of nitric oxide from photosensitive stores in the photorelaxation of the rabbit corpus cavernosum. Eur J Pharmacol 2003;459:263-267.
73. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980;209:823-825.
74. Gysemans CA, Cardozo AK, Callewaert H, Giulietti A, Hulshagen L, Bouillon R, Eizirik DL, Mathieu C. 1,25-dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: Implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005;146:1956-1964.
75. Narvaez CJ, Matthews D, Broun E, Chan M,Welsh J. Lean phenotype and resistance to diet-induced obesity in vitaminDreceptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. Endocrinology 2009;150: 651-661.
76. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690-693.
77. Boucher BJ, John WG, Noonan K. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;80:1666. author reply 1666-1667.
78. HiraniV. Relationship between vitaminDand hyperglycemia in older people from a nationally representative population survey. J Am Geriatr Soc 2011;59:1786-1792.
79. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. Diabetes Care 2004;27: 2813-2818.
80. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: A systematic review and meta-Analysis. Arch Dis Child 2008;93: 512-517.
81. de Boer IH, Tinker LF, Connelly S, Curb JD, Howard BV, Kestenbaum B, Larson JC, Manson JE, Margolis KL, Siscovick DS,Weiss NS. Calcium plus vitamin D supplementation and the risk of incident diabetes in the women's health initiative. Diabetes Care 2008;31:701-707.
82. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: A reanalysis of thewomen's health initiative (WHI) limited-Access data set. Am J Clin Nutr 2011;94:1144-1149.
83. Somjen D,Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005;111:1666-1671.
84. Danielsson C, Nayeri S, Wiesinger H, Thieroff-Ekerdt R, Carlberg C. Potent gene regulatory and antiproliferative activities of 20-methyl analogues of 1,25 dihydroxyvitamin D3. J Cell Biochem 1996;63:199-206.
85. Manolagas SC, ProvvediniDM,Murray EJ, TsoukasCD, Deftos LJ. The antiproliferative effect of calcitriol on human peripheral blood mononuclear cells. J Clin Endocrinol Metab 1986;63:394-400.
86. Kreindler JL, Steele C, Nguyen N, Chan YR, Pilewski JM, Alcorn JF, Vyas YM, Aujla SJ, Finelli P, Blanchard M, Zeigler SF, Logar A, Hartigan E, Kurs-Lasky M, Rockette H, Ray A, Kolls JK. Vitamin D3 attenuates th2 responses to Aspergillus fumigatus mounted by cd4+t cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010;120:3242-3254.
87. OhJ,Weng S, Felton SK, Bhandare S, Riek A, Butler B, Proctor BM, Petty M, Chen Z, Schechtman KB, Bernal-Mizrachi L, Bernal-Mizrachi C. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009;120:687-698.
88. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Int Med 2008;168:1174-1180.
89. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754-759.
90. Ignat M, Teletin M, Tisserand J, Khetchoumian K, Dennefeld C, Chambon P, Losson R, Mark M. Arterial calcifications and increased expression of vitaminDreceptor targets in mice lacking tif1alpha. Proc Natl Acad Sci USA 2008;105: 2598-2603.
91. Young KA, Snell-Bergeon JK, Naik RG, Hokanson JE, Tarullo D, Gottlieb PA, Garg SK, Rewers M. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care 2011;34:454-458.
92. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340-1349.
93. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2011:CD007470.
94. Autier P, Gandini S. VitaminDsupplementation and total mortality: A meta-Analysis of randomized controlled trials. Arch Intern Med 2007;167:1730-1737.
95. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M. Calcium/vitaminDsupplementation and cardiovascular events. Circulation 2007;115:846-854.
96. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. Br Med J 2003;326:469.
97. Wood AD, Secombes KR, Thies F, Aucott L, Black AJ, Mavroeidi A, Simpson WG, Fraser WD, Reid DM, Macdonald HM. Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors. A parallel-group, double-blind, placebo-controlled rct. J Clin Endocrinol Metab 2012;97:3557-3568.
98. LaCroix AZ, Kotchen J, Anderson G, Brzyski R, Cauley JA, Cummings SR, Gass M, Johnson KC,KoM, LarsonJ, Manson JE, Stefanick ML,Wactawski-Wende J. Calcium plus vitamin D supplementation and mortality in postmenopausal women: The women's health initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009;64:559-567.
99. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152:315-323.
100. Wang L, Song Y, Manson JE, Pilz S, MarzW, Michaelsson K, Lundqvist A, Jassal SK, Barrett-Connor E, Zhang C, Eaton CB,MayHT, Anderson JL, Sesso HD. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-Analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012;5:819-829.
101. Berggren M, Stenvall M, Olofsson B, Gustafson Y. Evaluation of a fall-prevention program in older people after femoral neck fracture: A one-year follow-up. Osteoporos Int 2008;19:801-809.
102. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M. Vitamin D as supplementary treatment for tuberculosis: A double-blind, randomized, placebo-controlled trial. Am J Respir Critical Care Med 2009;179:843-850.
103. Khajehdehi P. Effect of vitamins on the lipid profile of patients on regular hemodialysis. Scand J Urol Nephrol 2000;34:62-66.
104. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE. The vitamin D and omega-3 trial (vital): Rationale and design of a large randomized controlled trial of vitaminDand marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012;33:159-171.
105. Al Mheid I, Ramadan R, Kavtaradze N, Morris A, Ali S, Aznaouridis K, Quyyumi F, AlexanderRW, Brigham KL, Quyyumi A. Abstract 1723: Vitamin D levels are associated with exercise capacity and measures of endothelial function in healthy humans. Circulation 2009;120:s551.
106. Gordon DJ, Hyde J, TrostDC, WhaleyFS, Hannan PJ, JacobsDR, Ekelund LG. Cyclic seasonal variation in plasma lipid and lipoprotein levels: The lipid research clinics coronary primary prevention trial placebo group. J Clin Epidemiol 1988;41: 679-689.
107. Ponda MP, Dowd K, Finkielstein D, Holt PR, Breslow JL. The short-Term effects of vitaminDrepletion on cholesterol: A randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2012;32:2510-2515.
108. Thieden E, Jorgensen HL, Jorgensen NR, Philipsen PA, Wulf HC. Sunbed radiation provokes cutaneous vitaminDsynthesis inhumans-A randomized controlled trial. Photochem Photobiol 2008;84:1487-1492.
109. Vieth R. VitaminDtoxicity, policy, and science. J Bone Miner Res 2007;22(Suppl. 2): V64-68.
110. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol 1994;30:774-778.
111. Svobodova AR, Galandakova A, Sianska J, Dolezal D, Lichnovska R, Ulrichova J, Vostalova J. DNA damage after acute exposure of mice skin to physiological doses of UVB and UVA light. Arch Dermatol Res 2012;304:407-412.
112. Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: Mechanisms of action. Mol Aspects Med 2008;29:361-368.
113. Centers for Disease C, Prevention. Safer and healthier foods.MMWR Morb Mortal Wkly Rep 1999;48:905-913.
114. Welch TR, Bergstrom WH, Tsang RC. Vitamin D-deficient rickets: The reemergence of a once-conquered disease. J Pediatrics 2000;137:143-145.
115. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: What clinicians need to know. J Clin Endocrinol Metab 2011;96:53-58.
116. Tangpricha V. Vitamin D in food and supplements. Am J Clin Nutr 2012;95: 1299-1300.
117. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine S. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-1930.
118. Fauci AS. Harrison's Principles of Internal Medicine. Mcgraw Hill Professional. 2012:1online resource (xxxvii, 2754 p.
119. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta Jr. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007;11:315-321.
120. de Francisco AL. Medical therapy of secondary hyperparathyroidism in chronic kidney disease: Old and new drugs. Expert Opin Pharmacother 2006;7:2215-2224.
121. Baker K, Pehr K. Granuloma annulare associated with hypercalcemia secondary to hyperparathyroidism. Int J Dermatol 2006;45:1118-1120.